Welcome to MolDiag-PaCa

>> Publications



Professor Nick R Lemoine
MD PhD FRCPath FMedSci
Director of the Institute of Cancer
Centre Lead, Molecular Oncology

Dr Tatjana Crnogorac-Jurcevic
MD PhD
Senior Lecturer and Team Leader
Institute of Cancer


Overall research programme:

Professor Lemoine is the Director of both the Institute of Cancer and the Cancer Research UK Clinical Centre. He also leads the Centre for Molecular Oncology, where the research of four groups focuses on the molecular pathology of solid malignancies, gene transcription biology, cell survival signalling, and molecular therapeutics including gene therapy and vaccine approaches.
The Centre for Molecular Oncology aims to exploit the technologies of functional genomics to develop novel approaches for diagnosis, classification and treatment of human cancers. Advances in knowledge resulting from the sequencing of the human genome and the advent of high-throughput technologies now facilitate simultaneous analysis of the activity of many genes in cells and tissues, and the challenge is to translate such molecular profiles into clinical benefit for patients.

The main research interest of Dr Crnogorac-Jurcevic is to understand the molecular genetics of pancreatic cancer, particularly the earliest molecular changes in the development of this malignancy by utilising large-scale transcriptomic and proteomic analyses. She hopes to find a minimal set of biomarkers that will enable an early detection of pancreatic cancer with high levels of specificity and sensitivity at the stage when curative surgery is still possible. In addition to tissues, a particular focus in her work is the analysis of body fluids (plasma and urine), which will enable non-invasive diagnosis and monitoring of patients with this malignancy.
The second aspect of her studies is based on uncovering molecular signatures of micrometastatic disease. Thus selected genes/proteins would represent a target for novel therapeutics that could be used in conjunction with surgical treatment.


Role in the Integrated Project:

We are coordinating WP2 (Molecular alterations of preneoplastic lesions, early and advanced tumours: genomic, transcriptomic and proteomic profiles) and are also involved in WP1 (Epidemiology and patient resources), WP3 (RNA-based diagnostics), WP4 (Proteome based diagnostics) and WP6 (Molecular Imaging tools).


Group members involved:

  • Dr Tomohiko Harada
  • Dr Mark Weeks
  • Dr Deepak Hariharan
  • Tomasz Radon


Contact:

Molecular Oncology Unit, Institute of Cancer,
John Vane Science Centre, Charterhouse Square,
London EC1M 6BQ,
United Kingdom
Tel +44 (0)20 7014 0420
Fax +44 (0)20 7014 0461
http://www.cancer.qmul.ac.uk/